EUVIMEDEUVIMED entdecken
Crossref

Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases

Yinghui Zhang, Yadan Liu, Bing Jiang, Lifan Chen, Jie Hu, Buying Niu, Jie Chang, Zisheng Fan, Jingyi Zhou, Yajie Wang, Dan Teng, Ning Ma und 4 weitere

Science China Life Sciences · 2024-12 · 67 (12) · 2664-2677

DOI: 10.1007/s11427-024-2703-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science China Life Sciences, online erschienen am 22.08.2024. Verfasst von Yinghui Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai,…. Hauptthemen laut MEDLINE: Chalcones, Membrane Proteins, Interferon Regulatory Factor-3, NF-kappa B. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of STING inhibitors for the treatment of STING-related inflammatory diseases continues to encounter significant challenges. The activation of STING is a multi-step process that includes binding with cGAMP, self-oligomerization, and translocation from the endoplasmic reticulum to the Golgi apparatus, ultimately inducing the expression of IRF3 and NF-κB-mediated interferons and inflammatory cytokines. It has been demonstrated that disruption of any of these steps can effectively inhibit STING activation. Traditional structure-based drug screening methodologies generally focus on specific binding sites. In this study, a TransformerCPI model based on protein primary sequences and independent of binding sites is employed to identify compounds capable of binding to the STING protein. The natural product Licochalcone D (LicoD) is identified as a potent and selective STING inhibitor. LicoD does not bind to the classical ligand-binding pocket; instead, it covalently modifies the Cys148 residue of STING. This modification inhibits STING oligomerization, consequently suppressing the recruitment of TBK1 and the nuclear translocation of IRF3 and NF-κB. LicoD treatment ameliorates the inflammatory phenotype in Trex1-1- mice and inhibits the progression of DSS-induced colitis and AOM/DSS-induced colitis-associated colon cancer (CAC). In summary, this study reveals the potential of LicoD in treating STING-driven inflammatory diseases. It also demonstrates the utility of the TransformerCPI model in discovering allosteric compounds beyond the conventional binding pockets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChalconesMembrane ProteinsInterferon Regulatory Factor-3NF-kappa BAnimalsMiceHumansInflammationColitisMice, Inbred C57BLProtein Serine-Threonine KinasesSignal TransductionBinding SitesSTING Protein

Stichwörter der Autor:innen

Licochalcone DSTING inhibitorTransformerCPI modelcGAS-STING signalinginflammatory diseases

Substanzen

ChalconesMembrane ProteinsInterferon Regulatory Factor-3NF-kappa BProtein Serine-Threonine KinasesSting1 protein, mouseSTING ProteinSTING1 protein, human

Autor:innen und Institutionen

  • Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Shanghai Institute for Advanced Immunochemical Studies, and School of Life Science and Technology, Shanghai Tech University, Shanghai, 200031, China.
  • School of Physical Science and Technology, ShanghaiTech University, Shanghai, 200031, China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.

Zitieren

APA

Zhang, Y., Liu, Y., Jiang, B., Chen, L., Hu, J., Niu, B., Chang, J., Fan, Z., Zhou, J., Wang, Y., Teng, D., Ma, N., Wang, X., Yang, R., Zheng, M., & Zhang, S. (2024). Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases. Science China Life Sciences, 67(12), 2664-2677. https://doi.org/10.1007/s11427-024-2703-6

Vancouver

Zhang Y, Liu Y, Jiang B, Chen L, Hu J, Niu B, et al. Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases. Science China Life Sciences. 2024;67(12):2664-2677. doi:10.1007/s11427-024-2703-6

BibTeX
@article{Zhang2024,
  author = {Zhang, Yinghui and Liu, Yadan and Jiang, Bing and Chen, Lifan and Hu, Jie and Niu, Buying and Chang, Jie and Fan, Zisheng and Zhou, Jingyi and Wang, Yajie and Teng, Dan and Ma, Ning and Wang, Xiaofeng and Yang, Ruirui and Zheng, Mingyue and Zhang, Sulin},
  title = {Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases},
  journal = {Science China Life Sciences},
  year = {2024},
  volume = {67},
  number = {12},
  pages = {2664--2677},
  doi = {10.1007/s11427-024-2703-6}
}
Kostenlos starten →